Is cholinergic sensitivity a genetic marker for the affective disorders?

American Journal of Medical Genetics

Volumn 54, Issue 4, 1994, Pages 335-344

  Janowsky, D S ^a   Overstreet, D H ^a   Nurnberger, J I ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

acetylcholine; affective disorders; depression; genetics

Indexed keywords

ACETYLCHOLINE; ARECOLINE; BETA ENDORPHIN; CHOLINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLONIDINE; CORTICOTROPIN; DEANOL; DYFLOS; GROWTH HORMONE; HYDROCORTISONE; LITHIUM; METHYLPHENIDATE; NICOTINE; OXOTREMORINE; PHOSPHATIDYLCHOLINE; PHYSOSTIGMINE; PYRIDOSTIGMINE;

AFFECTIVE NEUROSIS; BEHAVIOR DISORDER; CHOLINERGIC ACTIVITY; CHOLINERGIC TRANSMISSION; GENETIC LINKAGE; GENETIC MARKER; HUMAN; NEUROENDOCRINE DISEASE; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER;

EID: 0028674101     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajmg.1320540412     Document Type: Review

References (88)

1. Bajada S (1982): A trial of choline chloride and physostigmine in Alzheimer's dementia. In Corkin S, Davis K, Growden J (eds): “ Alzheimer's Disease: A Report of Progress.” New York: Raven Press, pp 427–432.
2. Benca RM, Obermeyer WH, Thisted RA, Gillin JC (1992): Sleep and psychiatric disorders. A meta‐analysis. Arch Gen Psychiatry 49: 651–668.
3. Berger M, Hochli D Zulley J Lauer C Von Zerssen D (1985): Cholinomimetic drug RS86, REM sleep and depression. Lancet 1: 1385–1386.
4. Berger M, Lund R Bronisch T Von Zerssen D (1983): REM latency in neurotic and endogenous depression and the cholinergic REM induction test. Psychiatry Res 10: 113–123.
5. Berger M, Riemann D, Hochli D, Spiegel R (1989): The cholinergic rapid eye movement sleep induction test with RS‐86. Arch Gen Psychiatry 46: 421–428.
6. Berkowitz A, Sutton L, Janowsky DS, Gillin JC (1990): Pilocarpine, an orally active muscarinic cholinergic agonist, induces REM sleep and reduces delta sleep in normal volunteers. Psychiatry Res 33: 113–119.
7. Berrettini WH, Detera‐Wadleigh SD, Goldin LR, Martinez M, Tsieh WT, Hoehe M, Choi H, Muniec D, Ferraro TN, Guroff JG, Dazuba D, Harris N, Kron F, Nurnberger JL Jr, Alexander RC, Gershon ES (1991): Genomic screening for genes predisposing to bipolar disease. Psychiatr Genet 2: 191–208.
8. Bruni JF, Meites J (1978): Effects of cholinergic drugs on growth hormone release. Life Sci 23: 1351–1358.
9. Carroll BJ, Frazer A, Schless A, Mendels J (1973): Cholinergic reversal of manic symptoms. Lancet 1: 427–428.
10. Carroll BJ, Greden JF, Haskett R, Reinberg M, Abala AA, Martin FIR, Robin RT, Heath B, Sharp PT, McLeod WL, McLeod MF (1980): Neurotransmitter studies of neuroendocrine pathology in depression. Acta Psychiatr Scand “Suppl” 280: 183–189.
11. Casey DE (1979): Mood alterations during deanol therapy. Psychopharmacology (Berlin) 62: 187–191.
12. Charles HC, Lazeyras F Krishnan KRR Boyko OB, Payne M, Moore D (1993): Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy. Prog Neuropsychopharmacol Biol Psychiatry (in press).
13. Charney DS, Heninger GR, Sternberg DE, Hafstad KM, Giddings S, Landis DH (1982): Adrenergic receptor sensitivity in depression. Arch Gen Psychiatry 39: 290–294.
14. Davis BM, Davis KL (1980): Cholinergic mechanisms and anterior pituitary hormone secretion. Biol Psychiatry 15: 303–310.
15. Davis KL, Berger PA, Hollister LE, DeFraites E (1978): Physostigmine in man. Arch Gen Psychiatry 35: 119–122.
16. Davis KL, Hollister LE, Berger PA (1979): Choline chloride in schizophrenia. Am J Psychiatry 136: 1581–1584.
17. DeMet EM, Sokolski KA (1993): Pupillary response to pilocarpine in depression. Presented at Seattle meeting of the West Coast College of Biological Psychiatry.
18. Doerr P, Berger M (1983): Physostigmine‐induced escape from dexamethasone suppression in normal adults. Biol Psychiatry 18: 261–268.
19. Dube S, Kuman N Ettedgui A Pohl R, Jones D, Sitaram N (1985): Cholinergic REM induction response: separation of anxiety and depression. Biol Psychiatry 20: 408–418.
20. Edelstein P, Schultz JF, Hirschowitz J, Kanter DR, Garver DL (1981): Physostigmine and lithium response in the schizophrenia. Am J Psychiatry 138: 1078–1081.
21. El‐Yousef M, Janowsky DS, Davis JM, Rosenblatt JE (1973): Induction of severe depression in marijuana intoxicated individuals. Br J Addict 68: 321–325.
22. Gann H, Riemann D Hohagen F Dressing H, Muller WE, Berger M (1992): The sleep structure of patients with anxiety disorders in comparison to that of healthy controls and depressive patients under baseline conditions and after cholinergic stimulation. J Affective Disord 26: 179–190.
23. Gershon ES, Berrettini W Nurnberger JL Jr, Goldin LR (1987): Genetics of affective illness. In Meltzer HY (ed): “ Psychopharmacology: The Third Generation of Progress.” New York: Raven Press, pp 481–492.
24. Gershon S, Shaw FH (1961): Psychiatric sequelae of chronic exposure to organophosphorous insecticides. Lancet 1: 1371–1374.
25. Gillin JC, Sutton L Ruiz C Kelsoe J Dupont RM Darko D Risch SC, Golshan S, Janowsky D (1991): The cholinergic rapid eye movement induction test with arecoline in depression. Arch Gen Psychiatry 48: 264–270.
26. Glassman AH (1993): Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 150: 546–553.
27. Gora‐Maslak G, McClearn GE, Crabbe JC, Phillips TS, Belnap JK, Plomin R (1991): Use of recombinant inbred strains to identify quantitative trait loci in psychopharmacology. Psychopharmacology (Berlin) 104: 413–424.
28. Hobson JA, McCarley RW, Wyzinski PW (1975): Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups. Science 189: 55–58.
29. Hwang W, Tarricone B Hingtgen J Nurnberg JL Jr (in preparation): Identification of a locus on mouse chromosome 17 associated with the choline transporter using BXD recombinant inbred mice and quantitative trait loci analysis.
30. Janowsky DS, El‐Yousef MK, Davis JM (1974a): Antagonistic effects of physostigmine and methylphenidate in man. Am J Psychiatry 130: 1370–1376.
31. Janowsky DS, El‐Yousef MK, Davis JM (1974): Acetylcholine and depression. Psychosom Med 36: 248–257.
32. Janowsky DS, El‐Yousef MK, Davis JM, Sekerke HJ (1972): A cholinergic‐adrenergic hypothesis of mania and depression. Lancet 2: 632–635.
33. Janowsky DS, El‐Yousef MK, Davis JM, Sekerke HJ (1973b): Parasympathetic suppression of manic symptoms by physostigmine. Arch Gen Psychiatry 28: 542–547.
34. Janowsky DS, Risch SC (1984): Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorder and stress. Drug Dev Res 4: 125–142.
35. Janowsky DS, Risch SC (1987): Role of acetylcholine mechanisms in the affective disorders. In Meltzer HY (ed): “ Psychopharmacology: The Third Generation of Progress.” New York: Raven Press, pp 527–534.
36. Janowsky DS, Risch SC, Huey LY, Kennedy B, Ziegler M (1985): Effects of physostigmine on pulse, blood pressure and serum epinephrine levels. Am J Psychiatry 142: 738–740.
37. Janowsky DS, Risch SC, Judd LL, Huey LY, Parker DC (1981): Cholinergic supersensitivity in affect disorder patients: Behavioral and neuroendocrine observations. Psychopharmacol Bull 17: 129–132.
38. Janowsky DS, Risch SC, Parker D, Huey LY, Judd LL (1980): In creased vulnerability to cholinergic stimulation in affect disorder patients. Psychopharmacol Bull 16: 29–31.
39. Kaufman CA, Gillin JC, Hill B, O'Laughlin T, Phillips I, Gleenman JE, Wyatt RJ (1984): Muscarinic binding in suicides. Psychiatry Res 12: 47–56.
40. Kelsoe J Jr, Gillin J, Janowsky DS, Brown J, Risch SC, Lumkin B (1985): Failure to confirm muscarinic receptors on skin fibroblasts. N Engl J Med 312: 861–862.
41. Kendler K, Nenale MC, MacLean CL, Heath AC, Eaves LJ, Kessler RC (1993): Smoking and major depression: a causal analysis. Arch Gen Psychiatry 50: 36–43.
42. Lesch KP, Manji HK (1992): Signal‐transducing G proteins and antidepressant drugs: evidence for modulation of alpha subunit gene expression in rat brain. Biol Psychiatry 32: 549–579.
43. Meyerson LR, Wennogle LP, Abel MS (1982): Human brain receptor alterations in suicide victims. Pharmacol Biochem Behav 17: 159–163.
44. Modestin JJ, Hunger J, Schwartz RB (1973a): Uber die depressogene Wirkung von Physostigmine. Arch Psychiatrie Nervenkr 218: 67–77.
45. Modestin JJ, Schwartz RB, Hunger J (1973b): Zur Frage der Beeinflussung Schizophrener Symptome Physostigmine. Pharmacopsychiatria 9: 300–304.
46. Mohs R, Hollander E Haroutunian V Davidson M, Horvath T, Davis KL (1987): Cholinomimetics in Alzheimer's disease. Int J Neurosci 32: 775–776.
47. Nadi NS, Nurnberger JL Jr, Gershon ES (1984): Muscarinic cholinergic receptors on skin fibroblasts in familial affective disorder. N Engl J Med 311: 225–230.
48. Nurnberger JL Jr, Berrettini W, Mendelson WB, Sack B, Gershon ES (1989): Measuring cholinergic sensitivity: I. Arecoline effects in bipolar patients. Biol Psychiatry 25: 610–617.
49. Nurnberger JL Jr, Gershon ES, Sitaram N, Gillin JC, Brown G, Ebert M, Gold P, Jimerson D, Kessler L (1981): Dextroamphetamine and arecoline as pharmacogenetic probes in normals and remitted bipolar patients. Psychopharmacol Bull 17: 80–82.
50. Nurnberger JL Jr, Jimerson DC, Simmons‐Alling S (1983a): Behavioral, physiological and neuroendocrine response to arecoline in normal twins and well state bipolar patients. Psychiatry Res 9: 191–200.
51. Nurnberger JL Jr, Sitaram N, Gershon ES, Gillin JC (1983b): A twin study of cholinergic REM induction. Biol Psychiatry 18: 1161–1173.
52. Nurnberger JL Jr, Swanson CL, Simon JR, Hingtgen JN (1993): Cholinergic and serotonergic parameters differentiate inbred strains of mice. Pharmacol Biochem Behav (in press).
53. O'Keane V, O'Flynn K, Lucey J, Dinan TG (1992): Pyridostigmine‐induced growth hormone responses in healthy and depressed subjects–Evidence for cholinergic supersensitivity in depression. Psychol Med 22: 55–60.
54. Oppenheimer G, Ebstein R, Belmaker R (1979): Effects of lithium on the physostigmine‐induced behavioral syndrome and plasma cyclic GMP. J Psychiatr Res 14: 133–138.
55. Overstreet DH (1993): The Flinders Sensitive Line rats: a genetic animal model of depression. Neurosci Biobehav Rev 17: 51–68.
56. Overstreet DH, Janowsky DS, Pucilowski O, Rezvani AH (1993a): Muscarinic and serotonergic sensitivities and swim test immobility in crossbreeds of Flinders line rats. Presented at First International Congress on Psychiatric Genetics, New Orleans, LA.
57. Overstreet DH, Pucilowski O, Rezvani AH, Janowsky DS (1993b): Differential segregation of cholinergic and serotonergic sensitivity in crossbreeds of Flinders Line rats. Presented at 23rd annual meeting of Behavioral Genetics Association, Sydney, Australia.
58. Overstreet DH, Rezvani AH, Janowsky DS (1992a): Genetic animal models of depression and ethanol preference provide support for cholinergic and serotonergic involvement in depression and alcoholism. Biol Psychiatry 31: 919–936.
59. Overstreet DH, Russell RW (1982): Selective breeding for increased DFP sensitivity. Effects of cholinergic agonists and antagonists. Psychopharmacology (Berlin) 78: 150–154.
60. Overstreet DH, Russell RW, Crocker AD, Gillin JC, Janowsky DS (1988): Genetic and pharmacological models of cholinergic supersensitivity and affective disorders. Experientia 44: 465–472.
61. Overstreet DH, Russell RW, Hay DA, Crocker AD (1992b): Selective breeding for increased cholinergic function: biometrical genetic analysis of muscarinic responses. Neuropsychopharmacology 7: 197–204.
62. Overstreet DH, Russell RW, Helps SC, Messenger M (1979): Selective breeding for sensitivity to the anticholinesterase, DFP. Psychopharmacology 65: 15–20.
63. Pucilowski O, Overstreet DH (1993): Effect of chronic antidepressant treatment on responses to apomorphine in selectively bred rat strains. Brain Res Bull 32: 471–475.
64. Pucilowski O, Overstreet DH, Rezvani AH, Janowsky DS (1993): Chronic mild stress‐induced anhedonia: greater effect in a genetic rat model of depression. Physiol Behav (in press).
65. Rapaport MH, Risch SC, Gillin JC, Golshan S, Janowsky D (1991): The effects of physostigmine infusion on patients with panic disorder. Biol Psychiatry 29: 658–664.
66. Risch SC, Cohen PM, Janowsky DS, Kalin NH, Insel TR, Murphy DL (1981a): Physostigmine induction of depressive symptomatology in normal human subjects. Psychiatry Res 4: 89–94.
67. Risch SC, Janowsky DS, Gillin JC (1981b): Muscarinic supersensitivity of anterior pituitary ACTH and beta endorphin release in major depressive illness. Peptides 9: 789–792.
68. Risch SC, Janowsky DS, Kalin NH, Cohen RM, Aloi JA, Murphy DL (1982): Cholinergic beta endorphin hypersensitivity associated with depression. In Hanin I, Usdin E (eds): “ Biological Markers in Psychiatry and Neurology.” Oxford: Pergamon Press, pp 269–278.
69. Risch SC, Kalin NH, Janowsky DS (1981c): Cholinergic challenge in affective illness: behavioral and neuroendocrine correlates. J Clin Psychopharmacol 1: 186–192.
70. Risch SC, Siever LJ, Gillin JC (1983): Differential mood effects of arecoline in depressed patients and normal volunteers. Psychopharmacol Bull 19: 696–698.
71. Rowntree DW, Neven S, Wilson A (1950): The effect of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis. J Neurol Neurosurg Psychiatry 13: 47–62.
72. Schiller GD, Pucilowski O, Wienicke C, Overstreet DH (1992): Immobility‐reducing effects of antidepressants in a genetic animal model of depression. Brain Res Bull 28: 821–823.
73. Schittecatte M, Charles G Machowsky R Garcia J, Mendlewicz J, Wilmotte J (1992): Reduced clonidine rapid eye movement suppression in patients with primary major affective illness. Arch Gen Psychiatry 49: 637–642.
74. Schreiber W, Lauer CJ, Krumrey K, Holsboer F, Krieg JC (1992): Cholinergic REM sleep induction test in subjects at high risk for psychiatric disorders. Biol Psychiatry 32: 79–90.
75. Shiromani PJ, Overstreet DH, Levy D, Goodrich CA, Campbell SS, Gillin JC (1988): Increased REM sleep in rats selectively bred for cholinergic hyperactivity. Neuropsychopharmacology 1: 127–133.
76. Shopsin B, Janowsky DS, Davis JM, Gershon S (1975): Rebound phenomena in mania patients following physostigmine. Neuropsychobiology 1: 180–187.
77. Siever LJ, Risch SC, Murphy DL (1981): Central cholinergic‐adrenergic balance in the regulation of affective state. Psychiatry Res 5: 108–109.
78. Siever LJ, Uhde TW (1984): New studies and perspectives on the noradrenergic receptor system in depression: effects of the alpha‐2‐adrenergic agonist clonidine. Biol Psychiatry 19: 131–156.
79. Silva SG, Stern RA, Golden RA, Davidson EJ, Mason GA, Janowsky DS (1993): The effects of physostigmine on behavioral inhibition, cognitive processes, mood state and neuroendocrine functioning in healthy males. Biol Psychiatry (submitted for publication).
80. Sitaram N, Jones D, Dube S, Bell J, Rivard P (1985): Supersensitive ACh REM‐induction as a genetic vulnerability marker. Int J Neurosci 32: 777–778.
81. Sitaram N, Jones D Dube S Keshavan M Bell J, Davis A, Reynot PC (1987): The association of supersensitive cholinergic REM‐induction and affective illness within pedigrees. J Psychiatr Res 21: 487–497.
82. Sitaram N, Nurnberger J, Gershon ES, Gillin JC (1982): Cholinergic regulation of mood and REM sleep. A potential model and marker for vulnerability to depression. Am J Psychiatry 139: 571–576.
83. Stanley M (1983): New Research Abstracts of the Annual Meeting of the American Psychiatry Association, Washington, D. C.
84. Steinberg B, Weston S Trestman RL Condello V Temple J Mitchell D Gold D, Guralnik O, Siever J (1993): Affective instability in personality disordered patients correlates with mood response to physostigmine challenge. Biol Psychiatry 33: 86.
85. Tamminga C, Smith RC, Change S, Haraszti JS, Davis JM (1976): Depression associated with oral choline. Lancet 2: 905.
86. Tancer ME, Stein MB, Uhde TW (1993): Growth hormone response to intravenous clonidine in social phobia: comparison to patients with panic disorder and healthy workers. Biol Psychiatry 34: 591–595.
87. Tandon R, Greden JF (1989): Cholinergic hyperactivity and negative schizophrenic symptoms: A model of dopaminergic/cholinergic interactions in schizophrenia. Arch Gen Psychiatry 46: 745–753.
88. Tarricone B, Hingtgen J Nurnberger JL Jr (1993): The response of C57B/65, DBA/2S and BXD recombinant inbred mice to the Porsolt test and the restraint stress test. Psychiatr Genet 3: 186 (abstract).